These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
1214 related articles for article (PubMed ID: 26919154)
1. Comparison of neoadjuvant chemotherapy versus upfront surgery with or without chemotherapy for patients with clinical stage III esophageal squamous cell carcinoma. Matsuda S; Tsubosa Y; Sato H; Takebayashi K; Kawamorita K; Mori K; Niihara M; Tsushima T; Yokota T; Onozawa Y; Yasui H; Takeuchi H; Kitagawa Y Dis Esophagus; 2017 Feb; 30(2):1-8. PubMed ID: 26919154 [TBL] [Abstract][Full Text] [Related]
2. Failure of neoadjuvant chemotherapy for resectable esophageal squamous cell carcinoma. Okamura A; Watanabe M; Mine S; Kurogochi T; Yamashita K; Hayami M; Imamura Y; Ogura M; Ichimura T; Takahari D; Chin K Dis Esophagus; 2017 Sep; 30(9):1-8. PubMed ID: 28859367 [TBL] [Abstract][Full Text] [Related]
3. The prognostic significance of the positive circumferential resection margin in pathologic T3 squamous cell carcinoma of the esophagus with or without neoadjuvant chemotherapy. Okada N; Fujii S; Fujita T; Kanamori J; Kojima T; Hayashi R; Daiko H Surgery; 2016 Feb; 159(2):441-50. PubMed ID: 26391150 [TBL] [Abstract][Full Text] [Related]
4. Neoadjuvant chemotherapy with irinotecan and nedaplatin in a single cycle followed by esophagectomy on cT4 resectable esophageal squamous cell carcinoma: a prospective nonrandomized trial for short-term outcomes. Tian D; Zhang L; Wang Y; Chen L; Zhang KP; Zhou Y; Wen HY; Fu MY Dis Esophagus; 2019 Mar; 32(3):. PubMed ID: 30247659 [TBL] [Abstract][Full Text] [Related]
5. Prognostic Advantage of Docetaxel/Cisplatin/ 5-Fluorouracil Neoadjuvant Chemotherapy in Clinical Stage II/III Esophageal Squamous Cell Carcinoma due to Excellent Control of Preoperative Disease and Postoperative Lymph Node Recurrence. Yamashita K; Hosoda K; Moriya H; Katada C; Sugawara M; Mieno H; Komori S; Katada N; Watanabe M Oncology; 2017; 92(4):221-228. PubMed ID: 28110330 [TBL] [Abstract][Full Text] [Related]
6. Neoadjuvant versus adjuvant chemoradiation for stage II-III esophageal squamous cell carcinoma: a single institution experience. Chen Y; Hao D; Wu X; Xing W; Yang Y; He C; Wang W; Liu J; Wang J Dis Esophagus; 2017 Jul; 30(7):1-7. PubMed ID: 28475725 [TBL] [Abstract][Full Text] [Related]
7. Prognostic Factors in Patients Receiving Neoadjuvant 5-Fluorouracil plus Cisplatin for Advanced Esophageal Cancer (JCOG9907). Yokota T; Ando N; Igaki H; Shinoda M; Kato K; Mizusawa J; Katayama H; Nakamura K; Fukuda H; Kitagawa Y Oncology; 2015; 89(3):143-51. PubMed ID: 25895447 [TBL] [Abstract][Full Text] [Related]
8. Prognostic significance of pathological tumor response and residual nodal metastasis in patients with esophageal squamous cell carcinoma after neoadjuvant chemotherapy followed by surgery. Oguma J; Ozawa S; Koyanagi K; Kazuno A; Yamamoto M; Ninomiya Y; Yatabe K Esophagus; 2019 Oct; 16(4):395-401. PubMed ID: 31190104 [TBL] [Abstract][Full Text] [Related]
9. Neoadjuvant chemotherapy of triplet regimens of docetaxel/cisplatin/5-FU (DCF NAC) may improve patient prognosis of cStage II/III esophageal squamous cell carcinoma-propensity score analysis. Yamashita K; Katada N; Moriya H; Hosoda K; Mieno H; Katada C; Koizumi W; Hoshi K; Watanabe M Gen Thorac Cardiovasc Surg; 2016 Apr; 64(4):209-15. PubMed ID: 26868531 [TBL] [Abstract][Full Text] [Related]
10. Induction chemotherapy improved outcomes of patients with resectable esophageal cancer who received chemoradiotherapy followed by surgery. Jin J; Liao Z; Zhang Z; Ajani J; Swisher S; Chang JY; Jeter M; Guerrero T; Stevens CW; Vaporciyan A; Putnam J; Walsh G; Smythe R; Roth J; Yao J; Allen P; Cox JD; Komaki R Int J Radiat Oncol Biol Phys; 2004 Oct; 60(2):427-36. PubMed ID: 15380576 [TBL] [Abstract][Full Text] [Related]
11. Comparison of transthoracic esophagectomy with definitive chemoradiotherapy as initial treatment for patients with esophageal squamous cell carcinoma who could tolerate transthoracic esophagectomy. Matsuda S; Tsubosa Y; Niihara M; Sato H; Takebayashi K; Kawamorita K; Mori K; Tsushima T; Yokota T; Ogawa H; Onozawa Y; Yasui H; Takeuchi H; Kitagawa Y Ann Surg Oncol; 2015; 22(6):1866-73. PubMed ID: 25564176 [TBL] [Abstract][Full Text] [Related]
12. Effects of Neoadjuvant 5-Fluorouracil and Cisplatin Therapy in Patients with Clinical Stage II/III Esophageal Squamous Cell Carcinoma. Konishi H; Fujiwara H; Shiozaki A; Shoda K; Kosuga T; Kubota T; Okamoto K; Otsuji E Anticancer Res; 2018 Feb; 38(2):1017-1023. PubMed ID: 29374735 [TBL] [Abstract][Full Text] [Related]
13. Prognostic significance of the prognostic nutritional index in esophageal cancer patients undergoing neoadjuvant chemotherapy. Nakatani M; Migita K; Matsumoto S; Wakatsuki K; Ito M; Nakade H; Kunishige T; Kitano M; Kanehiro H Dis Esophagus; 2017 Aug; 30(8):1-7. PubMed ID: 28575242 [TBL] [Abstract][Full Text] [Related]
14. The role of postoperative adjuvant chemotherapy for lymph node-positive esophageal squamous cell carcinoma: a propensity score matching analysis. Qin RQ; Wen YS; Wang WP; Xi KX; Yu XY; Zhang LJ Med Oncol; 2016 Apr; 33(4):31. PubMed ID: 26922662 [TBL] [Abstract][Full Text] [Related]
15. Validity of upfront surgery for patients with unsuspected lymph node metastasis in esophageal cancer: a propensity scoring matching study. Park JK; Kim JJ; Moon SW; Cho DG J Cardiothorac Surg; 2018 Jun; 13(1):62. PubMed ID: 29880029 [TBL] [Abstract][Full Text] [Related]
16. Investigation of operative outcomes of thoracoscopic esophagectomy after triplet chemotherapy with docetaxel, cisplatin, and 5-fluorouracil for advanced esophageal squamous cell carcinoma. Akiyama Y; Iwaya T; Endo F; Chiba T; Takahara T; Otsuka K; Nitta H; Koeda K; Mizuno M; Kimura Y; Sasaki A Surg Endosc; 2018 Jan; 32(1):391-399. PubMed ID: 28664431 [TBL] [Abstract][Full Text] [Related]
17. Phase II feasibility study of preoperative concurrent chemoradiotherapy with cisplatin plus 5-fluorouracil and elective lymph node irradiation for clinical stage II/III esophageal squamous cell carcinoma. Hashimoto J; Kato K; Ito Y; Kojima T; Akimoto T; Daiko H; Hamamoto Y; Matsushita H; Katano S; Hara H; Tanaka Y; Saito Y; Nagashima K; Igaki H Int J Clin Oncol; 2019 Jan; 24(1):60-67. PubMed ID: 30109544 [TBL] [Abstract][Full Text] [Related]
18. Trimodality therapy of esophagectomy plus neoadjuvant chemoradiotherapy improves the survival of clinical stageĀ II/III esophageal squamous cell carcinoma patients. Fujiwara Y; Yoshikawa R; Kamikonya N; Nakayama T; Kitani K; Tsujie M; Yukawa M; Inoue M; Yamamura T Oncol Rep; 2012 Aug; 28(2):446-52. PubMed ID: 22664791 [TBL] [Abstract][Full Text] [Related]
19. [Patterns of recurrence in patients with stage pT3N0M0 thoracic esophageal squamous cell carcinoma after two-field esophagectomy]. Wang Y; Wang L; Yang Q; Li J; He M; Yao J; Qi Z; Li B; Qiao X Zhonghua Zhong Liu Za Zhi; 2016 Jan; 38(1):48-54. PubMed ID: 26796807 [TBL] [Abstract][Full Text] [Related]
20. Post-esophagectomy Adjuvant Chemotherapy Benefits Esophageal Cancer Patients. Sohda M; Saito H; Kuriyama K; Yoshida T; Kumakura Y; Honjyo H; Hara K; Ozawa D; Suzuki S; Tanaka N; Sakai M; Miyazaki T; Fukuchi M; Kuwano H In Vivo; 2019; 33(2):501-506. PubMed ID: 30804133 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]